So far, studies carried out in tumour biopsies and cfDNA have reported that alterations in MAPK pathway are predominant both in melanoma [34] and NSCLC [10, 11, 16] at BRAF-targeted therapy failure. This evidence concerns the gene BRAF and neoplasm.